诺纳生物,一家致力于前沿技术创新,并为合作伙伴提供涵盖靶点验证和新一代生物大分子药物从发现至临床前研发等Idea to IND(I to ITM)完整服务的国际化创新生物技术公司,今日宣布其合作伙伴辉瑞在2025年美国癌症研究协会(AACR)年会上公布了同类首创基于拓扑异构酶1抑制剂(TOP1i)的靶向人间皮素(MSLN)抗体偶联药物(ADC)PF-08052666(HBM9033;SGN-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.